Progress of Cancer Nano Medicine, Clinical Hurdles, and Opportunities

Abstract

Cancer is the second leading cause of mortality in the globe. One of the most severe flaws in most anticancer medicines is their lack of tumor selectivity. Nanomedicine for cancer treatment given intravenously to avoid renal clearance cannot pass through tight endothelial junctions in normal blood arteries and accumulate in plasma at high levels. In this chapter, we will look at the advancements of nanomedicine in all areas of pharmaceuticals. We will also discuss the challenges encountered during clinical testing and development of cancer medicines, as well as future opportunities.